BridgeMD
New treatment option for Pediatric Hodgkin's Disease
Official title Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.
ClinicalTrials.gov ID: NCT03500133
What this study is testing
What is Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.?
Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered. is an investigational medicine, being studied as a potential treatment for pediatric hodgkin's disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects. Patients of both genders, between 2 and 18 years, with newly diagnosed classical Hodgkin lymphoma are admitted.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 to 18
You may be able to join if
- Histopathological diagnosis of classical Hodgkin lymphoma.
- Normal renal, hepatic, pulmonary and metabolic function standards.
- Informed consent signed by patient and/or legal caretakers.
You likely can't join if
- Lymphocyte predominant nodular Hodgkin lymphoma
- Any form of immunodeficiency before diagnosis. (primary immunodeficiencies, trasplant recipients or immunosuppressive therapies of any kind including...
- Pregnancy and breastfeeding period.
- Sexually active female patients who do not accept an effective contraceptive method during therapy.
- Positive HIV serology.
- Penfigus or hepatic ductopenia.
See the full eligibility criteria
- Histopathological diagnosis of classical Hodgkin lymphoma.
- Normal renal, hepatic, pulmonary and metabolic function standards.
- Informed consent signed by patient and/or legal caretakers.
- Lymphocyte predominant nodular Hodgkin lymphoma
- Any form of immunodeficiency before diagnosis. (primary immunodeficiencies, trasplant recipients or immunosuppressive therapies of any kind including corticoid therapies during 28 days before diagnosis).
- Pregnancy and breastfeeding period.
- Sexually active female patients who do not accept an effective contraceptive method during therapy.
- Positive HIV serology.
- Penfigus or hepatic ductopenia.
- Hodgkin lymphoma as a secondary malignant disease.
The study team makes the final eligibility decision.
Where it's taking place
- Buenos Aires, Buenos Aires F.D., Argentina
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Buenos Aires, Buenos Aires F.D., Argentina. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.